Ascentage Pharma Group International (NASDAQ:AAPG) Hits New 12-Month Low – Here’s Why

Posted by George Bondi on Jun 5th, 2026

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) shares reached a new 52-week low during mid-day trading on Friday . The company traded as low as $17.10 and last traded at $17.57, with a volume of 5393 shares. The stock had previously closed at $18.28.

Analysts Set New Price Targets

A number of analysts recently issued reports on AAPG shares. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. BTIG Research restated a “buy” rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a report on Monday, April 13th. Finally, Deutsche Bank Aktiengesellschaft began coverage on Ascentage Pharma Group International in a report on Friday, April 24th. They issued a “buy” rating and a $40.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $46.67.

View Our Latest Analysis on Ascentage Pharma Group International

Ascentage Pharma Group International Trading Down 5.0%

The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57. The company has a 50-day simple moving average of $22.83 and a two-hundred day simple moving average of $25.31.

Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last released its earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The company had revenue of $24.72 million during the quarter. Sell-side analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Ascentage Pharma Group International

Institutional investors have recently bought and sold shares of the stock. XY Capital Ltd increased its stake in Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares in the last quarter. Citadel Advisors LLC purchased a new position in Ascentage Pharma Group International in the 3rd quarter worth about $383,000. ABC Arbitrage SA purchased a new position in Ascentage Pharma Group International in the 3rd quarter worth about $204,000. UBS Group AG increased its stake in Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares in the last quarter. Finally, Hsbc Holdings PLC purchased a new position in Ascentage Pharma Group International in the 2nd quarter worth about $391,000.

About Ascentage Pharma Group International

(Get Free Report)

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.